JP2008535927A - ポリマー及びパッセンジャー薬のミセル組成物 - Google Patents

ポリマー及びパッセンジャー薬のミセル組成物 Download PDF

Info

Publication number
JP2008535927A
JP2008535927A JP2008506677A JP2008506677A JP2008535927A JP 2008535927 A JP2008535927 A JP 2008535927A JP 2008506677 A JP2008506677 A JP 2008506677A JP 2008506677 A JP2008506677 A JP 2008506677A JP 2008535927 A JP2008535927 A JP 2008535927A
Authority
JP
Japan
Prior art keywords
peg
geldanamycin
prodrug
drug
rapamycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008506677A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008535927A5 (https=
Inventor
エス． クウォン，グレン
エル． フォレスト，マーカス
Original Assignee
ウィスコンシン アルムニ リサーチ ファンデイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウィスコンシン アルムニ リサーチ ファンデイション filed Critical ウィスコンシン アルムニ リサーチ ファンデイション
Publication of JP2008535927A publication Critical patent/JP2008535927A/ja
Publication of JP2008535927A5 publication Critical patent/JP2008535927A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2008506677A 2005-04-12 2006-04-12 ポリマー及びパッセンジャー薬のミセル組成物 Pending JP2008535927A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67046005P 2005-04-12 2005-04-12
US71600005P 2005-09-09 2005-09-09
PCT/US2006/013800 WO2006110862A2 (en) 2005-04-12 2006-04-12 Micelle composition of polymer and passenger drug

Publications (2)

Publication Number Publication Date
JP2008535927A true JP2008535927A (ja) 2008-09-04
JP2008535927A5 JP2008535927A5 (https=) 2008-12-25

Family

ID=37011968

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008506677A Pending JP2008535927A (ja) 2005-04-12 2006-04-12 ポリマー及びパッセンジャー薬のミセル組成物

Country Status (7)

Country Link
US (2) US8173167B2 (https=)
EP (1) EP1871343A2 (https=)
JP (1) JP2008535927A (https=)
KR (1) KR20080009196A (https=)
AU (1) AU2006235538A1 (https=)
CA (1) CA2603987A1 (https=)
WO (1) WO2006110862A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013516407A (ja) * 2009-12-30 2013-05-13 サムヤン バイオファーマシューティカルズ コーポレイション 改善された水溶解度を有するラパマイシン含有高分子ナノ粒子注射剤組成物及びその製造方法、並びに放射線療法と併用するための抗癌組成物
JP2013203680A (ja) * 2012-03-28 2013-10-07 Kobe Gakuin ビタミンｅ誘導体を含有する血中滞留性薬物キャリアー粒子

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003230761A1 (en) * 2002-03-29 2003-10-13 Abbott Laboratories Polymeric micelle formulations of hydrophobic compounds and methods
US20080082036A1 (en) * 2006-04-25 2008-04-03 Medtronic, Inc. Cerebrospinal fluid shunt having long term anti-occlusion agent delivery
US20100119529A1 (en) * 2006-05-12 2010-05-13 Furgeson Darin Y Elastin-like polymer delivery vehicles
DE102006038233A1 (de) * 2006-08-07 2008-02-14 Biotronik Vi Patent Ag Markerkomposit für medizinische Implantate
US20080102127A1 (en) * 2006-10-26 2008-05-01 Gao Hai Y Hybrid lipid-polymer nanoparticulate delivery composition
EP2131814A4 (en) * 2007-02-26 2011-08-03 Wisconsin Alumni Res Found POLYMIC MICROMS FOR THE RELEASE OF ACTIVE COMPOUNDS
WO2009006311A2 (en) * 2007-06-29 2009-01-08 Wisconsin Alumni Research Foundation Structuring effect of cholesterol in peg-phospholipid micelles, drug delivery of amphotericin b, and combination antifungals
WO2009009067A2 (en) * 2007-07-09 2009-01-15 Kwon Glen S Micelle encapsulation of theropeutic agents
US9422234B2 (en) * 2007-11-30 2016-08-23 The Johns Hopkins University Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer
US20090209757A1 (en) * 2008-01-10 2009-08-20 Santiago Ini Processes for the preparation and purification of paliperidone palmitate
US20090232762A1 (en) * 2008-03-11 2009-09-17 May Pang Xiong Compositions for delivery of therapeutic agents
US9271929B2 (en) * 2008-11-25 2016-03-01 École Polytechnique Fédérale De Lausanne (Epfl) Block copolymers and uses thereof
WO2010120599A2 (en) * 2009-04-16 2010-10-21 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
US20120082717A1 (en) * 2009-06-05 2012-04-05 Snu R&Db Foundation Complex, multilayer using the same, and device coated with the multilayer
EP2480207B1 (en) 2009-09-25 2016-11-09 Wisconsin Alumni Research Foundation Micelle encapsulation of therapeutic agents
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
WO2015161139A1 (en) 2014-04-16 2015-10-22 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
AU2016202636B2 (en) * 2009-12-30 2017-06-08 Caliber Therapeutics, Llc Balloon catheter systems for delivery of dry drug delivery vesicles to a vessel in the body
ES2845398T3 (es) 2009-12-30 2021-07-26 Caliber Therapeutics Llc Sistemas de catéter de balón para administración de vesículas de administración de fármacos secos a un vaso en el cuerpo
EP2382966A1 (en) * 2010-03-12 2011-11-02 DSM IP Assets B.V. Micelle compositions and process for the preparation thereof
MX374963B (es) 2011-04-29 2025-03-06 Selecta Biosciences Inc Nanoportadores sintéticos tolerogénicos para reducir las respuestas de anticuerpos.
US8945627B2 (en) * 2011-05-05 2015-02-03 Wisconsin Alumni Research Foundation Micelles for the solubilization of gossypol
CN102293736B (zh) * 2011-08-31 2013-06-05 兰州大学 紫杉醇-聚合物载药胶束制备工艺
CN103845290A (zh) 2012-12-03 2014-06-11 曼丽国际有限公司 Umirolimus及其衍生物用于治疗癌症的用途
WO2014093631A1 (en) * 2012-12-12 2014-06-19 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Formulations and carrier systems including compound interactive domains
CN103142479A (zh) * 2013-03-29 2013-06-12 中国药科大学 一种磷脂-维生素e琥珀酸聚乙二醇酯胶束的应用
BR122020023215B1 (pt) 2013-05-03 2022-11-22 Selecta Biosciences, Inc Composição e kit de nanocarreadores sintéticos tolerogênicos para reduzir ou prevenir anafilaxia em resposta a um antígeno não alergênico
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
WO2015013510A1 (en) 2013-07-25 2015-01-29 Ecole Polytechnique Federale De Lausanne Epfl High aspect ratio nanofibril materials
EP3089737B1 (en) * 2013-12-31 2021-11-03 Rapamycin Holdings, LLC Oral rapamycin nanoparticle preparations and use
US9700544B2 (en) * 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
HUP1400075A2 (hu) 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
US9855341B2 (en) 2014-02-19 2018-01-02 University of Pittsburgh—of the Commonwealth System of Higher Education Formulations and carrier systems including farnesylthiosalycylic moities
CA2954064C (en) 2014-07-02 2018-10-30 The Research Foundation For The State University Of New York Surfactant-stripped micelle compositions with high cargo to surfactant ratio
JP7242180B2 (ja) 2014-09-07 2023-03-20 セレクタ バイオサイエンシーズ インコーポレーテッド 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物
US11633355B2 (en) 2014-12-12 2023-04-25 Clemson University Research Foundation Multi-functional particles and methods of using the same
US10232050B1 (en) 2014-12-12 2019-03-19 Clemson University Multi-functional particles and methods of using the same
BR112018000217A2 (pt) * 2015-07-15 2018-09-04 Celator Pharmaceuticals Inc sistemas de distribuição de nanopartículas aperfeiçoados
CN105232459B (zh) * 2015-09-24 2018-10-16 沈阳药科大学 一种复溶自组装的水难溶性药物聚合物胶束组合物及其制备方法
ES3036482T3 (en) 2017-03-11 2025-09-19 Cartesian Therapeutics Inc Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US20190029970A1 (en) * 2017-07-31 2019-01-31 The Chinese University Of Hong Kong Fatty acid conjugated nanoparticles and uses thereof
US11857634B2 (en) 2018-04-20 2024-01-02 University of Pittsburgh—of the Commonwealth System of Higher Education Cationic amphiphilic polymers for codelivery of hydrophobic agents and nucleic acids
WO2020077170A1 (en) 2018-10-12 2020-04-16 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Small polymeric carriers for delivery of agents
KR102051593B1 (ko) 2018-11-15 2020-01-08 재단법인대구경북과학기술원 이중 반응형 양친매성 화합물, 이의 제조방법 및 이를 이용한 약물 전달체
AU2020287627A1 (en) 2019-06-04 2021-11-18 Selecta Biosciences, Inc. Formulations and doses of PEGylated uricase
CN111358754A (zh) * 2020-03-13 2020-07-03 广州白云山汉方现代药业有限公司 一种大环内酯类抗生素长循环乳剂及其制备方法
IT202000007228A1 (it) * 2020-04-06 2021-10-06 Diego Dolcetta SOMMINISTRAZIONE DI INIBITORI DI mTOR NEL SISTEMA NERVOSO CENTRALE
KR102701406B1 (ko) * 2021-10-18 2024-08-30 재단법인대구경북과학기술원 토코페롤을 포함하는 활성 산소 반응형 믹토암 양친매성 화합물, 이의 제조 방법, 및 이를 이용한 약물 전달체
WO2025095862A1 (en) * 2023-10-30 2025-05-08 National University Of Singapore A composition, a method of making the composition and its uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090414A (en) * 1970-05-20 2000-07-18 Life Science Labs, Inc. Method and composition to reduce cancer incidence
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
US5580899A (en) 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US6107332A (en) * 1995-09-12 2000-08-22 The Liposome Company, Inc. Hydrolysis-promoting hydrophobic taxane derivatives
ATE309235T1 (de) * 1995-09-12 2005-11-15 Zeneus Pharma Ltd Hydrolyse-einleitende hydrophobe taxane derivate
US6284267B1 (en) * 1996-08-14 2001-09-04 Nutrimed Biotech Amphiphilic materials and liposome formulations thereof
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6322810B1 (en) 1997-07-14 2001-11-27 Hayat Alkan-Onyuksel Materials and methods for making improved micelle compositions
US6217886B1 (en) * 1997-07-14 2001-04-17 The Board Of Trustees Of The University Of Illinois Materials and methods for making improved micelle compositions
AU1678900A (en) * 1998-08-11 2000-03-06 All India Institute Of Medical Sciences A novel liposomal formulation useful in treatment of cancer and other proliferation diseases
US6469132B1 (en) 1999-05-05 2002-10-22 Mcgill University Diblock copolymer and use thereof in a micellar drug delivery system
CA2408548C (en) * 2000-05-12 2008-03-11 Samyang Corporation Method for the preparation of polymeric micelle via phase separation of block copolymer
US6764507B2 (en) * 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
TWI246524B (en) * 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
WO2003002096A1 (en) 2001-06-28 2003-01-09 Wisconsin Alumni Research Foundation Methods and compositions for polyene antibiotics with reduced toxicity
US6872715B2 (en) 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
AU2003253645A1 (en) 2002-06-12 2003-12-31 The Board Of Trustees Of The University Of Illinois Phospholipid micelles in liposomes as solubilizers for water-insoluble compounds
US20040116360A1 (en) 2002-10-15 2004-06-17 Kwon Glen S. Encapsulation and deaggregation of polyene antibiotics using poly(ethylene glycol)-phospholipid micelles
US20050026893A1 (en) 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
AU2005269800B8 (en) 2004-07-19 2011-12-01 Jazz Pharmaceuticals Therapeutics, Inc. Particulate constructs for release of active agents

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013516407A (ja) * 2009-12-30 2013-05-13 サムヤン バイオファーマシューティカルズ コーポレイション 改善された水溶解度を有するラパマイシン含有高分子ナノ粒子注射剤組成物及びその製造方法、並びに放射線療法と併用するための抗癌組成物
JP2015078247A (ja) * 2009-12-30 2015-04-23 サムヤン バイオファーマシューティカルズ コーポレイシ 放射線療法と併用して肺癌の治療に有用なラパマイシン含有高分子ナノ粒子静脈注射用抗癌組成物
US9173841B2 (en) 2009-12-30 2015-11-03 Samyang Biopharmaceuticals Corporation Polymer nanoparticle injection formulation composition containing rapamycin with improved water solubility, preparation method thereof, and anticancer composition for combined use with radiotherapy
JP2013203680A (ja) * 2012-03-28 2013-10-07 Kobe Gakuin ビタミンｅ誘導体を含有する血中滞留性薬物キャリアー粒子

Also Published As

Publication number Publication date
WO2006110862A3 (en) 2007-07-05
US20120309780A1 (en) 2012-12-06
AU2006235538A1 (en) 2006-10-19
WO2006110862A9 (en) 2008-08-07
EP1871343A2 (en) 2008-01-02
US9107814B2 (en) 2015-08-18
US8173167B2 (en) 2012-05-08
US20060251710A1 (en) 2006-11-09
WO2006110862A2 (en) 2006-10-19
KR20080009196A (ko) 2008-01-25
CA2603987A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
US9107814B2 (en) Micelle composition of polymer and passenger drug
Straubinger Biopharmaceutics of paclitaxel (Taxol): formulation, activity, and pharmacokinetics
JP7012124B2 (ja) リポソーム組成物および医薬組成物
US20060177495A1 (en) Polymer-lipid delivery vehicles
US20060222716A1 (en) Colloidal solid lipid vehicle for pharmaceutical use
CN108289833B (zh) 用于递送囊封剂的稳定的已组装纳米结构
US20100203114A1 (en) Micelle encapsulation of therapeutic agents
JP2002535242A (ja) 新規な粒子状剤型
WO2011038278A2 (en) Micelle encapsulation of therapeutic agents
Lv et al. Capsaicin-loaded folic acid-conjugated lipid nanoparticles for enhanced therapeutic efficacy in ovarian cancers
KR101132626B1 (ko) 난용성 약물의 전달을 위한 고밀도지단백 나노입자의 제조방법
JP2006506344A (ja) 癌治療のための小胞封入コルチコステロイド
Jang et al. Improved tumor targeting and antitumor activity of camptothecin loaded solid lipid nanoparticles by preinjection of blank solid lipid nanoparticles
US20090324741A1 (en) Injectable polymer-lipid blend
AU2018384096B2 (en) Amphiphilic block copolymers, micelles, and methods for treating or preventing heart failure
ES2314210T3 (es) Composicion para tratamiento de trastornos inflamatorios.
US8859001B2 (en) Fenoldopam formulations and pro-drug derivatives
CN110200920B (zh) 一种还原敏感药物组合物及其制备和应用
Radhi et al. Preparation and in vitro evaluation of synthetic high-density lipoproteins as parenteral drug delivery system for tamoxifen citrate
Chu PRINT® nanoparticle parameters to improve docetaxel PK/PD
Howard Evaluation of the Physicochemical Properties and Stability of Solid Lipid Nanoparticles Designed for the Delivery of Dexamethasone to Tumors
Ao et al. Polymer Micelle Formulations of Proteasome Inhibitor Carfilzomib for

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081104